JP7741108B2 - インターロイキン２９変異体タンパク質 - Google Patents

インターロイキン２９変異体タンパク質

Info

Publication number
JP7741108B2
JP7741108B2 JP2022572748A JP2022572748A JP7741108B2 JP 7741108 B2 JP7741108 B2 JP 7741108B2 JP 2022572748 A JP2022572748 A JP 2022572748A JP 2022572748 A JP2022572748 A JP 2022572748A JP 7741108 B2 JP7741108 B2 JP 7741108B2
Authority
JP
Japan
Prior art keywords
protein
seq
interleukin
pharmaceutical composition
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022572748A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023527048A (ja
JP2023527048A5 (enExample
Inventor
▲楊▼柳
李岩
▲馮▼静
郭万▲軍▼
潘海
Original Assignee
杭州先▲為▼▲達▼生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 杭州先▲為▼▲達▼生物科技有限公司 filed Critical 杭州先▲為▼▲達▼生物科技有限公司
Publication of JP2023527048A publication Critical patent/JP2023527048A/ja
Publication of JP2023527048A5 publication Critical patent/JP2023527048A5/ja
Application granted granted Critical
Publication of JP7741108B2 publication Critical patent/JP7741108B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2022572748A 2020-05-27 2021-02-08 インターロイキン２９変異体タンパク質 Active JP7741108B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020092613 2020-05-27
CNPCT/CN2020/092613 2020-05-27
PCT/CN2021/075907 WO2021238302A1 (zh) 2020-05-27 2021-02-08 一种白细胞介素29突变体蛋白

Publications (3)

Publication Number Publication Date
JP2023527048A JP2023527048A (ja) 2023-06-26
JP2023527048A5 JP2023527048A5 (enExample) 2023-10-03
JP7741108B2 true JP7741108B2 (ja) 2025-09-17

Family

ID=78745522

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022572748A Active JP7741108B2 (ja) 2020-05-27 2021-02-08 インターロイキン２９変異体タンパク質

Country Status (6)

Country Link
US (1) US12703728B2 (enExample)
EP (1) EP4159748A4 (enExample)
JP (1) JP7741108B2 (enExample)
CN (1) CN115667291B (enExample)
AU (1) AU2021280623B9 (enExample)
WO (1) WO2021238302A1 (enExample)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013531477A (ja) 2010-05-03 2013-08-08 ブリストル−マイヤーズ スクイブ カンパニー 血清アルブミン結合性分子
CN105085658A (zh) 2014-05-14 2015-11-25 北京凯因科技股份有限公司 一种白细胞介素29突变体及聚乙二醇衍生物
JP2017503505A (ja) 2014-01-08 2017-02-02 プロ—ジット ソウル バイオテクノロジー （ベイジン） カンパニー リミテッド 融合ポリペプチドおよび使用方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101031316A (zh) 2004-07-29 2007-09-05 津莫吉尼蒂克斯公司 Il－28和il－29治疗癌症和自身免疫性疾病的用途
US7351689B2 (en) 2004-07-29 2008-04-01 Zymogenetics, Inc. Use of IL-28 and IL-29 to treat cancer and autoimmune disorders
JP2009502803A (ja) 2005-07-20 2009-01-29 ザイモジェネティクス， インコーポレイテッド Ｉｌ−２８およびｉｌ−２９のシステイン欠失変異体、ならびにそれを用いる抗ウイルス法
CN103224951A (zh) 2013-01-25 2013-07-31 江南大学 人白细胞介素29成熟肽第35位精氨酸定点突变为赖氨酸的变异体及其制备方法
CN103224952A (zh) 2013-01-25 2013-07-31 江南大学 人白细胞介素29成熟肽第33位赖氨酸、35位精氨酸定点突变为精氨酸、赖氨酸的变异体及其制备方法
CN103923209B (zh) 2014-05-13 2016-06-22 北京凯因科技股份有限公司 一种Lambda干扰素突变体及聚乙二醇衍生物
CN105085657A (zh) 2014-05-14 2015-11-25 北京凯因科技股份有限公司 一种干扰素突变体及聚乙二醇衍生物
CN104402988A (zh) 2014-12-12 2015-03-11 江南大学 一种人白细胞介素-29的重组变异体及其制备方法
CN112694526B (zh) * 2020-05-27 2023-01-20 杭州先为达生物科技有限公司 一种白细胞介素29突变体蛋白
CN112870336B (zh) * 2021-02-24 2022-06-14 杭州先为达生物科技有限公司 一种白细胞介素29突变体蛋白制剂

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013531477A (ja) 2010-05-03 2013-08-08 ブリストル−マイヤーズ スクイブ カンパニー 血清アルブミン結合性分子
JP2017503505A (ja) 2014-01-08 2017-02-02 プロ—ジット ソウル バイオテクノロジー （ベイジン） カンパニー リミテッド 融合ポリペプチドおよび使用方法
CN105085658A (zh) 2014-05-14 2015-11-25 北京凯因科技股份有限公司 一种白细胞介素29突变体及聚乙二醇衍生物

Also Published As

Publication number Publication date
JP2023527048A (ja) 2023-06-26
EP4159748A4 (en) 2024-02-21
AU2021280623A1 (en) 2023-02-02
CN115667291B (zh) 2025-08-05
EP4159748A1 (en) 2023-04-05
US20230265144A1 (en) 2023-08-24
WO2021238302A1 (zh) 2021-12-02
AU2021280623B9 (en) 2024-03-14
US12703728B2 (en) 2026-08-11
CN115667291A (zh) 2023-01-31
AU2021280623B2 (en) 2024-02-29

Similar Documents

Publication Publication Date Title
CN113498417B (zh) 多肽、其制备方法和用途
US20180298075A1 (en) Interferon Analogs
US20230348880A1 (en) Soluble ace2 and fusion protein, and applications thereof
CA2862391A1 (en) Stabilized antiviral fusion helices
CN113292638A (zh) 用于抗冠状病毒感染的多肽药物及其方法和应用
CN113150107B (zh) 一种白细胞介素29突变体蛋白
CN112870336B (zh) 一种白细胞介素29突变体蛋白制剂
US11299518B2 (en) Fusion respiratory syncytial virus inhibitors and use thereof
CN115772227A (zh) 新型冠状病毒SARS-CoV-2的Delta变异株疫苗与应用
CN115667291B (zh) 一种白细胞介素29突变体蛋白
WO2021164576A1 (zh) 用于抗冠状病毒感染的药物及其应用
JP2023500577A (ja) アルファ（ｖ）ベータ（６）インテグリン結合タンパク質の計算設計
CN111825773B (zh) 重组人TSG6-IFNα融合蛋白及其制备方法以及其作为抗病毒药物的应用
CN117304317B (zh) Ace2受体特异性结合肽及其应用
CN101671390A (zh) 人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途
US20230374091A1 (en) Annexin a5 compositions and methods
CN115385998B (zh) 稳定的iii型干扰素蛋白及其融合蛋白
EP4267166A1 (en) Blockade of sars-cov-2 infection using hydrocarbon stapled peptides
CN108822190B (zh) 多肽及其药物组合物和用途
WO2021139315A1 (zh) PEG修饰的可抑制gp96的多肽、其制备方法及用途
CA3178840C (en) Method of treating an inflammatory disorder
JP7185874B2 (ja) 抗ウイルス剤としてのラビリントペプチン
HK40083738A (en) Soluble ace2 and fusion protein, and applications thereof
US20070003565A1 (en) Use of hab18g/cd147 molecule as target for antiviral antagonists and thus obtained antiviral antagonist

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230925

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250526

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250819

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250904

R150 Certificate of patent or registration of utility model

Ref document number: 7741108

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150